Extended Data Fig. 8: The effect of Selinexor combined with AKT inhibition on mouse weight and hematopoietic cell compartment.
a) Dose-escalation study assessing mouse weight in disease naïve C57BL/6 mice. Mice were treated until Day 4 with indicated treatment regimens (n = 3 biologically independent mice). P values calculated using a two-way ANOVA; data are presented as + /- mean s.d. b) Dose-escalation study assessing white blood cell count in disease naïve C57BL/6 mice. Mice were treated until Day 4 with indicated treatment regimens (n = 3 biologically independent mice). P values calculated using a two-way ANOVA; data are presented as + /- mean s.d. c) Immunoblot depicting protein level of Tp53 in DsRed+ MLL-AF9 cells from mice treated in vivo with Selinexor for indicated duration. Each timepoint representants an independent biologic replicate. Representative immunoblots of n = 2 biologically independent experiments yielding similar results. Vinculin shown as loading control. d-n) Flow cytometric measurement of various hematopoietic cell types, each defined by gating strategies labeled on respective y-axes, in C57BL/6 mice treated with vehicle, chemotherapy (1 mg/kg doxorubicin and 100 mg/kg cytarabine), or the combination of 65 mg/kg ipatasertib and 15 mg/kg selinexor. Data are presented as mean + /- s.d. for n = 4 biologically independent replicates. Where indicated, P values computed using unpaired (two-sided) t-test.
